AIM Vaccine (HKG:6660) recently submitted a clinical trial application to the US Food and Drug Administration for its mRNA RSV (respiratory syncytial virus) vaccine.
The drugmaker said results from third-party preclinical tests showed that the group's mRNA RSV vaccine had significantly higher humoral and cellular immunity than those of the internationally
marketed mRNA RSV control vaccines, according to a Wednesday bourse filing.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。